290 related articles for article (PubMed ID: 26722556)
21. Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma: A Case-Control Study.
Wang Y; Wei T; Xiong J; Chen P; Wang X; Zhang L; Gao L; Zhu J
Medicine (Baltimore); 2015 Oct; 94(43):e1879. PubMed ID: 26512603
[TBL] [Abstract][Full Text] [Related]
22. Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population.
Wang YX; Zhao L; Wang XY; Liu CM; Yu SG
Endocrine; 2012 Jun; 41(3):526-31. PubMed ID: 22194161
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
24. The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.
Kotlarek M; Kubiak A; Czetwertyńska M; Świerniak M; Gierlikowski W; Kolanowska M; Bakuła-Zalewska E; Jhiang SM; Jażdżewski K; Wójcicka A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495389
[TBL] [Abstract][Full Text] [Related]
25. Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population.
Zhang Q; Song F; Zheng H; Zhu X; Song F; Yao X; Zhang L; Chen K
Thyroid; 2013 Jan; 23(1):38-44. PubMed ID: 22973979
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
28. Association between a promoter polymorphism (rs2192752, -1028A/C) of interleukin 1 receptor, type I (IL1R1) and location of papillary thyroid carcinoma in a Korean population.
Park SW; Kim MK; Kwon KH; Kim J
Int J Immunogenet; 2012 Dec; 39(6):501-7. PubMed ID: 22594576
[TBL] [Abstract][Full Text] [Related]
29. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
30. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules.
Rezaei M; Khamaneh AM; Zarghami N; Vosoughi A; Hashemzadeh S
BMC Cancer; 2019 Jul; 19(1):690. PubMed ID: 31307429
[TBL] [Abstract][Full Text] [Related]
31. Lysine-Specific Demethylase 1 Affects the Progression of Papillary Thyroid Carcinoma via HIF1α and microRNA-146a.
Long M; Zhu Y; Chen Z; Lin S; Peng X; Luo D; Li H; Tan L
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32303750
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA POLR2E rs3787016 is associated with the risk of papillary thyroid carcinoma in Chinese population.
Chen B; Li J; Yi C; Jiao Y; Gu X; Feng X
Pathol Res Pract; 2018 Jul; 214(7):1040-1044. PubMed ID: 29724531
[TBL] [Abstract][Full Text] [Related]
33. The effect of TP53 and P21 gene polymorphisms on papillary thyroid carcinoma susceptibility and clinical/pathological features.
Heidari Z; Harati-Sadegh M; Arian A; Maruei-Milan R; Salimi S
IUBMB Life; 2020 May; 72(5):922-930. PubMed ID: 31895498
[TBL] [Abstract][Full Text] [Related]
34. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
35. The association of common functional polymorphisms in mir-146a and mir-196a2 and hepatocellular carcinoma risk: evidence from a meta-analysis.
Peng Q; Li S; Lao X; Chen Z; Li R; Deng Y; Qin X
Medicine (Baltimore); 2014 Dec; 93(29):e252. PubMed ID: 25546664
[TBL] [Abstract][Full Text] [Related]
36. The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies.
Wang J; Wang Q; Liu H; Shao N; Tan B; Zhang G; Wang K; Jia Y; Ma W; Wang N; Cheng Y
Mutagenesis; 2012 Nov; 27(6):779-88. PubMed ID: 22952151
[TBL] [Abstract][Full Text] [Related]
37. Expression Levels of miR-30a-5p in Papillary Thyroid Carcinoma: A Comparison Between Serum and Fine Needle Aspiration Biopsy Samples.
Igci YZ; Ozkaya M; Korkmaz H; Bozgeyik E; Bayraktar R; Ulasli M; Erkilic S; Eraydin A; Oztuzcu S
Genet Test Mol Biomarkers; 2015 Aug; 19(8):418-23. PubMed ID: 26047355
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.
Bingül İ; Vural P; Doğru-Abbasoğlu S; Çil E; Uysal M
J Clin Lab Anal; 2017 Nov; 31(6):. PubMed ID: 27925342
[TBL] [Abstract][Full Text] [Related]
39. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
Maruei-Milan R; Heidari Z; Salimi S
J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
[TBL] [Abstract][Full Text] [Related]
40. Variants in microRNA genes in familial papillary thyroid carcinoma.
Tomsic J; Fultz R; Liyanarachchi S; Genutis LK; Wang Y; Li W; Volinia S; Jazdzewski K; He H; Wakely PE; Senter L; de la Chapelle A
Oncotarget; 2017 Jan; 8(4):6475-6482. PubMed ID: 28031538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
